Topics

Pediatric CNS tumors | Treatment | Targeted therapy | Dabrafenib

Home > Publications > Topics > Pediatric CNS tumors > Treatment > Targeted therapy > Dabrafenib

Wahid MA, Khan MT, Hussain JM, Malik H, Umar SA, Mughal S, Hasanain M, Anjum MU, Mahmmoud Fadelallah Eljack M.
Emerging paradigm: Molecularly targeted therapy with Dabrafenib and Trametinib in recurring pediatric gliomas with BRAF mutations: A narrative review.
Medicine (Baltimore). 2024 Dec 6;103(49):e40735. doi: 10.1097/MD.0000000000040735. PMID: 39654184. Review. ˍ

Suzuki M, Koga Y, Kawasaki T, Ueda T, Yamamoto S, Goto H, Kishimoto J, Ishida E, Todaka K, Sonoda KH, Oda Y, Koji Y, Sakai Y, Ohga S.
Access Program for Unapproved and Off-Label Drug Use in Pediatric BRAF V600E-Mutated Brain Tumors in Japan.
Pediatr Blood Cancer. 2025 Jan 6:e31510. doi: 10.1002/pbc.31510. PMID: 39762715. Interventional study. ˍ

Campino GA, Shrot S, Constantini S, Roth J, Toren A, Lurye M, Yalon-Oren M.
Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation.
Childs Nerv Syst. 2025 Dec 21;41(1):429. doi: 10.1007/s00381-025-07084-w. PMID: 41423525. Case report. ˍ